Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Clin Mol Hepatol. 2019;25(3):283-293.   Published online 2018 Nov 13     DOI: https://doi.org/10.3350/cmh.2018.0054
Citations to this article as recorded by Crossref logo
The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis
Georgia Zeng, Benjamin R. Holmes, Saleh A. Alqahtani, Upkar S. Gill, Patrick T. F. Kennedy
Frontiers in Gastroenterology.2024;[Epub]     CrossRef
Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis
Sixing Shen, Lingyan Pan
Experimental and Therapeutic Medicine.2024;[Epub]     CrossRef
Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen
World Journal of Hepatology.2024; 16(3): 465.     CrossRef
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li
Journal of Viral Hepatitis.2024; 31(7): 372.     CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz
Heliyon.2024; 10(18): e37990.     CrossRef
Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study
Fadi Abu Baker, Abdel-Rauf Zeina, Randa Taher, Saif Abu Mouch, Ariel Israel
Journal of Clinical Medicine.2024; 13(18): 5608.     CrossRef
Effect of dyslipidemia on HBsAg clearance in nucleos(t)ide analogues-experienced chronic hepatitis B patients treated with peginterferon alfa
Kaimin Song, Lan Ren, Yunyun Qian, Huitong Wang, Zhixiang Guo, Huatang Zhang, Yijie Lin, Yijuan Zheng, Dawu Zeng, Yongjun Zhou, Zhijun Su, Xueping Yu
BMC Infectious Diseases.2024;[Epub]     CrossRef
Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus
Hua-Dong Li, Ya-Nan Liu, Shuang Wu, Xu-Feng Quan, Xiao-Yan Wang, Tian-Dan Xiang, Shu-Meng Li, Ling Xu, Tong Wang, Hua Wang, Xin Zheng
World Journal of Hepatology.2024; 16(12): 1395.     CrossRef
Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis
Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung‐Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H.‐W. Leung, Rajneesh Kumar, Jeong‐Hoon Lee, Amir Shlomai, Man‐Fung Yuen, Wai‐Kay Seto
Hepatology.2023; 77(5): 1735.     CrossRef
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao
Heliyon.2023; 9(1): e13113.     CrossRef
Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg‐positive chronic hepatitis B
Yanhua Tang, Rong Fan, Zhixian Lan, Qing Xie, Jiping Zhang, Xieer Liang, Hao Wang, Deming Tan, Jun Cheng, Shijun Chen, Qin Ning, Xuefan Bai, Min Xu, Xinyue Chen, Junqi Niu, Junping Shi, Hong Ren, Zhiliang Gao, Maorong Wang, Xiaoguang Dou, Jinlin Hou, Jian
Journal of Medical Virology.2023;[Epub]     CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
JHEP Reports.2023; 5(9): 100810.     CrossRef
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vince
Clinical and Molecular Hepatology.2023; 29(3): 705.     CrossRef
Predictors of treatment efficacy with nucleos(t)ide analogues for chronic hepatitis B
T. H. Nguyen, L. Yu. Ilchenko, L. I. Melnikova, K. K. Kyuregyan, I. V. Gordeychuk, N. L. Bondarenko
Experimental and Clinical Gastroenterology.2023; (4): 77.     CrossRef
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeongjun Song
Nutrients.2023; 15(18): 3970.     CrossRef
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Sang Hoon Ahn
Alimentary Pharmacology & Therapeutics.2022; 55(1): 97.     CrossRef
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia
BMC Cancer.2022;[Epub]     CrossRef
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B
Yi-Cheng Chen, Chao-Wei Hsu, Rong-Nan Chien, Dar-In Tai
Medicine.2022; 101(25): e29269.     CrossRef
Clinical impact and mechanisms in hepatitis B virus infection concurrent with non-alcoholic fatty liver disease
Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li
Chinese Medical Journal.2022;[Epub]     CrossRef
Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease
Jin Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Healthcare.2022; 10(11): 2268.     CrossRef
Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B
博诗 陈
Advances in Clinical Medicine.2022; 12(11): 10453.     CrossRef
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim
Journal of Gastroenterology and Hepatology.2021; 36(5): 1317.     CrossRef
Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
Jin Won Chang, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Gut and Liver.2021; 15(1): 117.     CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Korean Medical Science.2021;[Epub]     CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Cancers.2021; 13(14): 3424.     CrossRef
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik
Hepatology International.2021; 15(4): 892.     CrossRef
Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment
Xiu-Juan Chang, Yi-Wen Shi, Jing Wang, Hua-Bao Liu, Yan Chen, Xiao-Ning Zhu, Yong-Ping Chen, Zu-Jiang Yu, Qing-Hua Shang, Lin Tan, Qin Li, Li Jiang, Guang-Ming Xiao, Liang Chen, Wei Lu, Xiao-Yu Hu, Qing-Hua Long, Lin-Jing An, Zi-Yuan Zou, Vincent Wai-Sun
Hepatobiliary & Pancreatic Diseases International.2021; 20(5): 416.     CrossRef
No influence of hepatic steatosis on the 3‐year outcomes of patients with quiescent chronic hepatitis B
Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Viral Hepatitis.2021; 28(11): 1545.     CrossRef
Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model
Yuanqin Duan, Zhiwei Chen, Hu Li, Wei Shen, Yi Zeng, Mingli Peng, Peng Hu
Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Journal of Korean Medical Science.2020;[Epub]     CrossRef
Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
Yi-Cheng Chen, Wen-Juei Jeng, Chao-Wei Hsu, Chun-Yen Lin
BMC Gastroenterology.2020;[Epub]     CrossRef
Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park
Clinical and Molecular Hepatology.2020; 26(3): 364.     CrossRef
Letter: risk of hepatocellular carcinoma in immune‐tolerant phase of chronic hepatitis B—authors’ reply
Han Ah Lee, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2020; 52(5): 913.     CrossRef
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam
Microorganisms.2020; 8(10): 1526.     CrossRef
Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply
Han Ah Lee, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2020; 52(6): 1094.     CrossRef
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?
Jung Hwan Yu, Jin-Woo Lee
Clinical and Molecular Hepatology.2019; 25(3): 280.     CrossRef
Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease
Seung Up Kim, Mi Young Jeon, Tae Seop Lim
The Korean Journal of Gastroenterology.2019; 74(6): 341.     CrossRef